Cargando…

Meta-analysis of trimetazidine treatment for cardiomyopathy

To explore the effect of trimetazidine (TMZ) in cardiomyopathy treatment. Literatures, related with TMZ treatment for cardiomyopathy, were retrieved between 1990 and February 2018 in the Pubmed, Embase, and Cochrane Library systems. Cardiopulmonary exercise testing [resting heart rate (RHR), peak he...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Qian, Niu, Zhaozhuo, Ma, Liqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997798/
https://www.ncbi.nlm.nih.gov/pubmed/29654171
http://dx.doi.org/10.1042/BSR20171583
_version_ 1783331112352743424
author Fan, Qian
Niu, Zhaozhuo
Ma, Liqing
author_facet Fan, Qian
Niu, Zhaozhuo
Ma, Liqing
author_sort Fan, Qian
collection PubMed
description To explore the effect of trimetazidine (TMZ) in cardiomyopathy treatment. Literatures, related with TMZ treatment for cardiomyopathy, were retrieved between 1990 and February 2018 in the Pubmed, Embase, and Cochrane Library systems. Cardiopulmonary exercise testing [resting heart rate (RHR), peak heart rate (PHR), peak systolic blood pressure (PSBP), and resting systolic blood pressure (RSBP)] and echocardiographic results [left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), systolic wall thickening score index (SWTSI), left ventricular end-systolic diameter (LVESD), and left ventricular end-diastolic diameter (LVEDD)] were merged to detect the publication bias. Total 898 patients with cardiomyopathy were divided into two groups: TMZ-treated group (n=456) and control group (n=442). There was no difference in the improvement of cardiomyopathy between the TMZ and control group. No publication bias was shown for PHR (t= 0.9791, P=0.5067). There were significant differences in LVEF, LVESV, SWTSI, LVESD, and LVEDD between the TMZ group and the control group. TMZ-treatment significantly increased the level of LVEF (95% confidence interval (CI): 5.46–7.84, P<0.001), and reduced the level of LVESV (95% CI: −18.73 to −7.77, P<0.001), SWTSI (95% CI: −0.47 to −0.15, Z = −3.85, P=0.001), LVESD (95% CI: −1.09 to −0.08, P<0.001), and LVEDD (95% CI: −0.55 to −0.26, P=0.023). There was no publication bias except for LVEDV (t = 2.5456, P=0.0438). TMZ is effective for cardiomyopathy treatment and worth to popularize in clinic.
format Online
Article
Text
id pubmed-5997798
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-59977982018-06-13 Meta-analysis of trimetazidine treatment for cardiomyopathy Fan, Qian Niu, Zhaozhuo Ma, Liqing Biosci Rep Research Articles To explore the effect of trimetazidine (TMZ) in cardiomyopathy treatment. Literatures, related with TMZ treatment for cardiomyopathy, were retrieved between 1990 and February 2018 in the Pubmed, Embase, and Cochrane Library systems. Cardiopulmonary exercise testing [resting heart rate (RHR), peak heart rate (PHR), peak systolic blood pressure (PSBP), and resting systolic blood pressure (RSBP)] and echocardiographic results [left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), systolic wall thickening score index (SWTSI), left ventricular end-systolic diameter (LVESD), and left ventricular end-diastolic diameter (LVEDD)] were merged to detect the publication bias. Total 898 patients with cardiomyopathy were divided into two groups: TMZ-treated group (n=456) and control group (n=442). There was no difference in the improvement of cardiomyopathy between the TMZ and control group. No publication bias was shown for PHR (t= 0.9791, P=0.5067). There were significant differences in LVEF, LVESV, SWTSI, LVESD, and LVEDD between the TMZ group and the control group. TMZ-treatment significantly increased the level of LVEF (95% confidence interval (CI): 5.46–7.84, P<0.001), and reduced the level of LVESV (95% CI: −18.73 to −7.77, P<0.001), SWTSI (95% CI: −0.47 to −0.15, Z = −3.85, P=0.001), LVESD (95% CI: −1.09 to −0.08, P<0.001), and LVEDD (95% CI: −0.55 to −0.26, P=0.023). There was no publication bias except for LVEDV (t = 2.5456, P=0.0438). TMZ is effective for cardiomyopathy treatment and worth to popularize in clinic. Portland Press Ltd. 2018-06-12 /pmc/articles/PMC5997798/ /pubmed/29654171 http://dx.doi.org/10.1042/BSR20171583 Text en © 2018 The Author(s). http://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Articles
Fan, Qian
Niu, Zhaozhuo
Ma, Liqing
Meta-analysis of trimetazidine treatment for cardiomyopathy
title Meta-analysis of trimetazidine treatment for cardiomyopathy
title_full Meta-analysis of trimetazidine treatment for cardiomyopathy
title_fullStr Meta-analysis of trimetazidine treatment for cardiomyopathy
title_full_unstemmed Meta-analysis of trimetazidine treatment for cardiomyopathy
title_short Meta-analysis of trimetazidine treatment for cardiomyopathy
title_sort meta-analysis of trimetazidine treatment for cardiomyopathy
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997798/
https://www.ncbi.nlm.nih.gov/pubmed/29654171
http://dx.doi.org/10.1042/BSR20171583
work_keys_str_mv AT fanqian metaanalysisoftrimetazidinetreatmentforcardiomyopathy
AT niuzhaozhuo metaanalysisoftrimetazidinetreatmentforcardiomyopathy
AT maliqing metaanalysisoftrimetazidinetreatmentforcardiomyopathy